CD8A and neoplasm: It has been reported that the therapy combining anti-CD39 and anti-PD1 mAbs can further slow tumor growth and that the inhibition of CD39 enzyme function can make the tumor model with inherent drug resistance sensitive to PD1 antibody (11, 38).This may be because CD39 mAb and PD-1 mAb can recover the ability of CD8+T cells to produce cytokines.